LGVN
Longeveron Inc.
There isn't enough reported data to score LGVN yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
LGVN Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Unavailable |
LGVN's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
LGVN PE Valuation
LGVN has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
LGVN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| -- | |
| Limited | |
| High |
Analysts expect LGVN's losses to shrink, with revenue growing.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
LGVN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$62.80 | +$35.42 |
| Q2 2024 | -$87.40 | +$7.82 |
| Q1 2024 | -$96.10 | -$0.88 |
| Q4 2023 | -$102.00 | -$11.78 |
| Q3 2023 | -$98.22 | -$7.93 |
| Q2 2023 | -$95.22 | -$4.93 |
| Q1 2023 | -$95.22 | -$5.93 |
OSCR has the stronger earnings trend. Trailing diluted EPS is down 164% for LGVN versus OSCR up 147%.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
LGVN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $115K | -16% |
| Q2 2026 | $287K | -9.2% |
| Q1 2026 | $398K | +4.5% |
| Q4 2025 | $365K | -39% |
| Q3 2025 | $137K | -82% |
| Q2 2025 | $316K | -32% |
| Q1 2025 | $381K | -30% |
| Q4 2024 | $603K | +857% |
LGVN's revenue has slid since its 2020 peak: $115,000 last quarter, down 16% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -6258% | -923 points |
| Q2 2026 | -2150% | -442 points |
| Q1 2026 | -1200% | +160 points |
| Q4 2025 | -1479% | -769 points |
| Q3 2025 | -5336% | -4734 points |
| Q2 2025 | -1708% | -960 points |
| Q1 2025 | -1360% | -614 points |
| Q4 2024 | -710% | +7925 points |
LGVN's operating margin was −6258% last quarter, down 922 points from the same quarter a year ago, near the bottom of its range since 2019.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over LGVN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over LGVN on profitability, with a higher operating margin.
LGVN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2.8M | +$2.4M |
| Q2 2026 | -$5.8M | -$2M |
| Q1 2026 | -$4.4M | +$354K |
| Q4 2025 | -$5.3M | -$1.9M |
| Q3 2025 | -$5.1M | -$1.8M |
| Q2 2025 | -$3.8M | +$1M |
| Q1 2025 | -$4.7M | -$1.6M |
| Q4 2024 | -$3.4M | +$775K |
LGVN has burned cash in almost every quarter: −$18M over the past year, against −$17M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over LGVN on cash generation, producing positive trailing cash flow while its opponent burns cash.
LGVN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +159% | +400K shares |
| 1 year | +208% | +440K shares |
| 3 years | +243% | +461K shares |
LGVN has 650,988 diluted shares, up 208% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2022 | $141,000 |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over LGVN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
LGVN Net Leverage
LGVN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
LGVN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.1 | Neutral |
| Stochastic | 11.1 | Oversold |
LGVN's weekly RSI is 40 (neutral) and its Stochastic is 11 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
LGVN PE vs Healthcare Sector
LGVN has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
LGVN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.16 | 38% above |
| 20 week MA | $4.85 | 39% below |
| 50 week MA | $6.35 | 53% below |
| 100 week MA | $9.53 | 69% below |
| 200 week MA | $83.3 | 96% below |
LGVN has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 96% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over LGVN on trend strength, trading above more of its moving averages.
LGVN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $741.0 | $1,370.0 | +85% |
| 2022 | $1,370.0 | $327.0 | -76% |
| 2023 | $327.0 | $136.0 | -58% |
| 2024 | $136.0 | $17.5 | -87% |
| 2025 | $17.5 | $5.32 | -70% |
| 2026 YTD | $5.32 | $2.97 | -44% |
LGVN has finished four years in a row lower, and it's down 44% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over LGVN on returns for 2026, with the stronger performance.